KGbio
Stephanie Sunandar is currently working at KGbio as an Associate in Business Development & Licensing. Prior to this, Stephanie gained experience at Uppsala University as a Graduate Student in Innovative Medicine and a Research Intern at the Department of Medical Cell Biology. Stephanie also interned at SciLifeLab and University of Groningen, focusing on precision cancer medicine and molecular medicine. Stephanie has a strong background in biotechnology, supported by their Bachelor's degree from Atma Jaya Catholic University of Indonesia. Throughout their education and various internships, Stephanie has been involved in research and laboratory work, demonstrating their passion for medical innovation and biologics.
KGbio
KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals. Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).